- Home
- HSHP vs OMER Comparison
HSHP vs OMER Comparison
Compare HSHP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- OMER
- Stock Information
- Founded
- HSHP 2021
- OMER 1994
- Country
- HSHP Bermuda
- OMER United States
- Employees
- HSHP N/A
- OMER N/A
- Industry
- HSHP
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- OMER Health Care
- Exchange
- HSHP Nasdaq
- OMER Nasdaq
- Market Cap
- HSHP 282.3M
- OMER 240.5M
- IPO Year
- HSHP 2023
- OMER 2009
- Fundamental
- Price
- HSHP $7.25
- OMER $4.47
- Analyst Decision
- HSHP
- OMER Hold
- Analyst Count
- HSHP 0
- OMER 2
- Target Price
- HSHP N/A
- OMER N/A
- AVG Volume (30 Days)
- HSHP 117.2K
- OMER 202.7K
- Earning Date
- HSHP 01-01-0001
- OMER 11-11-2024
- Dividend Yield
- HSHP 6.06%
- OMER N/A
- EPS Growth
- HSHP N/A
- OMER N/A
- EPS
- HSHP 0.58
- OMER N/A
- Revenue
- HSHP $112,303,000.00
- OMER N/A
- Revenue This Year
- HSHP $284.85
- OMER N/A
- Revenue Next Year
- HSHP $16.28
- OMER N/A
- P/E Ratio
- HSHP $12.66
- OMER N/A
- Revenue Growth
- HSHP 919.64
- OMER N/A
- 52 Week Low
- HSHP $4.51
- OMER $1.13
- 52 Week High
- HSHP $9.76
- OMER $5.68
- Technical
- Relative Strength Index (RSI)
- HSHP 47.33
- OMER 63.45
- Support Level
- HSHP $6.79
- OMER $4.01
- Resistance Level
- HSHP $7.21
- OMER $4.68
- Average True Range (ATR)
- HSHP 0.17
- OMER 0.19
- MACD
- HSHP 0.06
- OMER 0.03
- Stochastic Oscillator
- HSHP 76.40
- OMER 73.13
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.